Table 3.

Cancer hazard ratios (HRs) by baseline statin use.

	Endometrial cancera						Ovarian cancerb
	N	Case	Annualized %	Mean fup (y)	Age-adjusted HR	Multivariable adjusted HR	N	Case	Annualized %	Mean fup (y)	Age-adjusted HR	Multivariable adjusted HR
Statin
No	87,365	1299	0.12%	12.15	1.00	1.00	117,028	701	0.05%	12.62	1.00	1.00
Yes	6653	78	0.10%	11.47	0.78 (0.62–0.98)	0.74 (0.59–0.94)	9225	62	0.06%	11.87	1.09 (0.84–1.42)	1.15 (0.89–1.50)
Statin type
No use	87,365	1299	0.12%	12.15	1.00	1.00	117,028	701	0.05%	12.62	1.00	1.00
Atorvastatin		6	0.11%	10.40	0.83 (0.37–1.85)	0.65 (0.27–1.56)		0	0.00%	10.84	NA	NA
Fluvastatin	508	15	0.17%	11.35	1.30 (0.78–2.17)	1.13 (0.65–1.95)	708	7	0.05%	11.63	1.01 (0.48–2.12)	1.06 (0.50–2.24)
Lovastatin	783	18	0.09%	11.85	0.66 (0.42–1.06)	0.67 (0.42–1.06)	1110	18	0.06%	12.31	1.15 (0.72–1.83)	1.21 (0.75–1.93)
Pravastatin	1770	17	0.10%	11.38	0.77 (0.47–1.24)	0.79 (0.49–1.27)	2428	18	0.07%	11.79	1.42 (0.89–2.27)	1.52 (0.95–2.44)
Simvastatin	1482 1947	21	0.09%	11.50	0.72 (0.47–1.11)	0.68 (0.43–1.05)	2042 2696	17	0.05%	11.89	1.05 (0.65–1.70)	1.09 (0.67–1.77)
Statin category
No use	87,365	1299	0.12%	12.15	1.00	1.00	117,028	701	0.05%	12.62	1.00	1.00
Lipophilic	5008	60	0.10%	11.49	0.80 (0.62–1.04)	0.74 (0.56–0.97)	6942	42	0.05%	11.89	0.98 (0.72–1.34)	1.03 (0.75–1.41)
Hydrophilic	1482	17	0.10%	11.38	0.77 (0.47–1.24)	0.79 (0.49–1.27)	2042	18	0.07%	11.79	1.42 (0.89–2.27)	1.52 (0.95–2.44)
Statin potency
No use	87,365	1299	0.12%	12.15	1.00	1.00	117,028	701	0.05%	12.62	1.00	1.00
High	2455	27	0.10%	11.27	0.74 (0.51–1.09)	0.67 (0.45–1.00)		17	0.04%	11.67	0.84 (0.52–1.37)	0.88 (0.55–1.43)
Medium	1482	17	0.10%	11.38	0.77 (0.47–1.24)	0.79 (0.49–1.27)	3404	18	0.07%	11.79	1.42 (0.89–2.27)	1.52 (0.95–2.44)
Low	2553	33	0.11%	11.70	0.85 (0.60–1.21)	0.80 (0.56–1.15)	2042 3538	25	0.06%	12.09	1.10 (0.74–1.65)	1.16 (0.78–1.74)
Statin duration
0	87,365	1299	0.12%	12.15	1.00	1.00	117,028	701	0.05%	12.62	1.00	1.00
<1 year	2192	23	0.09%	11.36	0.72 (0.47–1.08)	0.64 (0.42–0.99)	3034	18	0.05%	11.73	0.97 (0.61–1.55)	1.03 (0.64–1.64)
1–<3 years	2207	28	0.11%	11.54	0.84 (0.58–1.22)	0.80 (0.54–1.18)	2171	21	0.06%	11.92	1.12 (0.72–1.73)	1.19 (0.77–1.84)
≥3 y	2091	26	0.11%	11.49	0.82 (0.55–1.20)	0.81 (0.55–1.19)	2923	21	0.06%	11.94	1.16 (0.75–1.79)	1.21 (0.78–1.87)

All models contain strata for trial, WHI extension study, and age group. Base model was adjusted by continuous age.

Multivariate model adjusted for age (continuous), BMI (continuous), ethnicity, smoking status, education, current medical provider, baseline HT use, baseline HT duration.

^aWomen reporting hysterectomy at WHI baseline excluded; women with self-report of hysterectomy during follow-up were censored when reported.

^bWomen with history of ovarian cancer, bilateral and unknown oophorectomy at WHI baseline were excluded.